Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 12/2012

01-12-2012 | Short Communication

Low body mass index as a risk factor of moderate to severe oral mucositis in oral cancer patients with radiotherapy

Authors: Nobue Saito, Yutaka Imai, Takashi Muto, Toshimi Sairenchi

Published in: Supportive Care in Cancer | Issue 12/2012

Login to get access

Abstract

Purpose

The association between body mass index (BMI) and oral mucositis in oral cancer patients receiving radiotherapy is unclear. This study examined whether low BMI could be a risk factor for oral mucositis in oral cancer patients receiving radiotherapy.

Methods

Between April 2007 and March 2011, a total of 33 inpatients with oral cancer receiving radiotherapy were recruited. They were followed from the beginning of radiotherapy to discharge from hospital. All patients had no mucositis when radiotherapy started. The odds ratio (OR) and 95 % confidence interval (CI) of BMI for incident grade 2 and grade 3 mucositis were calculated by use of univariable logistic regression models.

Results

All patients developed oral mucositis (grade 1 in 39.4 %, grade 2 in 30.3 %, grade 3 in 30.3 %), with the maximum grade occurring at an average of 32.4 days. Compared with normal BMI (≥22.0), the OR of low BMI (<22.0) for moderate to severe mucositis was 9.07 (95 % CI, 1.72-47.68).

Conclusions

Low BMI may be a risk factor of moderate to severe oral mucositis.
Literature
1.
Vera-Llonch M, Oster G, Hagiwara M, Sonis S (2006) Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma—risk factors and clinical consequences. Cancer 106:329–336PubMedCrossRef
2.
McCarthy GM, Awde JD, Ghandi H, Vincent M, Kocha WI (1998) Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. Oral Oncol 34:484–490PubMedCrossRef
3.
Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L, Zilberberg MD (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66:253–262PubMedCrossRef
4.
Ikebe T, Seki K, Nakamura S, Takenoshita Y, Nakayama H, Shinohara M, Shirasuna K (2005) Severity of oral mucositis correlates with the response of oral cancer to preoperative radiochemotherapy. Int J Oral Maxillofac Surg 34:642–645PubMedCrossRef
5.
Sonis ST (1998) Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34:39–43PubMedCrossRef
6.
Logan RM, Gibson RJ, Sonis ST, Keefe DMK (2007) Nuclear factor-kappa B (NF-kappa B) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 43:395–401PubMedCrossRef
7.
Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, Forastiere A, Ang KK (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26:3582–3589PubMedCrossRef
8.
Kazemian A, Kamian S, Aghili M, Hashemi FA, Haddad P (2009) Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial. Eur J Cancer Care 18:174–178CrossRef
9.
Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, McCollum AD, Brady D, O'Connell MJ, Mayer RJ, Cummings B, Willett C, Macdonald JS, Benson AB, Fuchs CS (2004) Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from intergroup trial 0114. J Clin Oncol 22:648–657PubMedCrossRef
10.
Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Benson AB, Macdonald JS, Fuchs CS (2003) Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 98:484–495PubMedCrossRef
11.
Raber-Durlacher JE, Weijl NI, Abu Saris M, de Koning B, Zwinderman AH, Osanto S (2000) Oral mucositis in patients treated with chemotherapy for solid tumors: a retrospective analysis of 150 cases. Support Care Cancer 8:366–371PubMedCrossRef
12.
Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM (2004) Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol 22:1268–1275PubMedCrossRef
13.
Raber-Durlacher JE (1999) Current practices for management of oral mucositis in cancer patients. Support Care Cancer 7:71–74PubMedCrossRef
14.
Dreizen S (1990) Oral complications of cancer therapies. Description and incidence of oral complications. NCI Monogr 9:11–15PubMed
15.
Benoist S, Panis Y, Alves A, Valleur P (2000) Impact of obesity on surgical outcomes after colorectal resection. Am J Surg 179:275–281PubMedCrossRef
Metadata
Title
Low body mass index as a risk factor of moderate to severe oral mucositis in oral cancer patients with radiotherapy
Authors
Nobue Saito
Yutaka Imai
Takashi Muto
Toshimi Sairenchi
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 12/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1620-7

Other articles of this Issue 12/2012

Supportive Care in Cancer 12/2012 Go to the issue

Original Article

Lung cancer and rehabilitation—what are the barriers? Results of a questionnaire survey and the development of regional lung cancer rehabilitation standards and guidelines

Original Article

A randomized controlled trial comparing two types of pneumatic compression for breast cancer-related lymphedema treatment in the home

Original Article

A qualitative exploration of the role of primary care in supporting colorectal cancer patients

Review Article

Randomised controlled trials of yoga interventions for women with breast cancer: a systematic literature review

Letter to the Editor

Are neutropenic patients at an increased risk of infection?

Letter to the Editor

Response to “A cross-sectional study of constipation and laxative use in advanced cancer patients: insights for revision of current practise”
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits